Research shows heart failure drug meets some outcome goals

11/7/2012 | MedPage Today

Study data presented at the American Heart Association meeting and published in The Lancet showed serelaxin, a drug for acute heart failure, met one of two primary end points in improving dyspnea. The University of California at San Francisco study also found a significant decrease in cardiovascular deaths.

View Full Article in:

MedPage Today

Published in Brief:

SmartBrief Job Listings for Health Care